Effect of selective CCK<inf>1</inf> receptor antagonism on accommodation and tolerance of intestinal gas in functional gut disorders

Beatriz Lobo, Jordi Serra, Massimo D'Amato, Lucio Rovati, Juan R. Malagelada, Javier Santos, Fernando Azpiroz

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)


© 2016 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd. Background: Participants with functional gut disorders develop gas retention and symptoms in response to intestinal gas loads that are well tolerated by healthy subjects. To determine the role of cholecystokinin (CCK1) receptors on gas transit and tolerance in women with functional gut disorders. Methods: In 12 healthy women, and 24 women with functional gut disorders (12 dyspepsia and 12 constipation-predominant irritable bowel syndrome) gas was infused into the jejunum at 12mL/min for 3h with simultaneous duodenal lipid infusion (intralipid 1kcal/min), while measuring anal gas evacuation and abdominal symptoms on a 0-6 score scale. Triple-blind paired studies during iv infusion of dexloxiglumide (2.5mg/kg bolus plus 5mg/kgh continuous infusion), a selective CCK1 inhibitor, or saline (control) were performed in random order. Results: During saline infusion participants with functional gut disorders developed significantly greater gas retention and abdominal symptoms than healthy subjects (394±40mL vs 265±35mL and 2.8±0.3 vs 1.9±0.4 highest abdominal symptom score, respectively; P<0.05 for both). Dexloxiglumide increased gas retention in both groups (514±35mL and 439±60mL, respectively; P=0.033 vs saline for both); however, despite the larger retention, dexloxiglumide reduced abdominal symptoms (2.3±0.2 score and 0.8±0.3 score, respectively; P=0.05 vs saline for both). Post-hoc analysis showed that, the decrease in abdominal symptoms was more pronounced in those participants with functional gut disorders with higher basal abdominal symptoms than in the rest (P=0.037). Conclusion: Inhibition of CCK1 receptors by dexloxiglumide increases intestinal gas retention and reduces abdominal symptoms in response to by intestinal gas loads. European Clinical Trials Database (EudraCT 2005-003338-16).
Original languageEnglish
Pages (from-to)288-293
JournalJournal of Gastroenterology and Hepatology (Australia)
Issue number2
Publication statusPublished - 1 Feb 2016


  • CCK receptor 1
  • Cholecystokinin
  • Dexloxiglumide
  • Functional gut symptoms
  • Intestinal gas
  • Intestinal motility
  • Intestinal sensitivity


Dive into the research topics of 'Effect of selective CCK<inf>1</inf> receptor antagonism on accommodation and tolerance of intestinal gas in functional gut disorders'. Together they form a unique fingerprint.

Cite this